APA (7th ed.) Citation

IB, K., P, W., D, V., M, S., K, K., CS, F., . . . M, K. (2025). Temporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion. Journal for immunotherapy of cancer, 13(8), . https://doi.org/10.1136/jitc-2024-010465

Chicago Style (17th ed.) Citation

IB, Kilic, et al. "Temporal Optimization of CD25-biased IL-2 Agonists and Immune Checkpoint Blockade Leads to Synergistic Anticancer Activity Despite Robust Regulatory T Cell Expansion." Journal for Immunotherapy of Cancer 13, no. 8 (2025). https://doi.org/10.1136/jitc-2024-010465.

MLA (9th ed.) Citation

IB, Kilic, et al. "Temporal Optimization of CD25-biased IL-2 Agonists and Immune Checkpoint Blockade Leads to Synergistic Anticancer Activity Despite Robust Regulatory T Cell Expansion." Journal for Immunotherapy of Cancer, vol. 13, no. 8, 2025, https://doi.org/10.1136/jitc-2024-010465.